Aryloxypropanolamine and catecholamine ligand interactions with the beta(1)-adrenergic receptor: evidence for interaction with distinct conformations of beta(1)-adrenergic receptors.

Pharmacological responses to aryloxypropanolamines were examined in cells expressing rat or human beta(1)-adrenergic receptors (ARs) using adenylyl cyclase assays. The aryloxypropanolamines CGP 12177 and LY 362884, originally developed as beta(3)-AR agonists, were found to stimulate the beta(1)-AR. Interestingly, both CGP 12177 and LY 362884 exhibited an anomalous biphasic effect on beta(1)-AR. Low concentrations of either CGP 12177 or LY 362884 potently blocked isoproterenol-induced stimulation of beta(1)-AR, whereas higher concentrations of these compounds stimulated the beta(1)-AR. The unusual interaction of these aryloxypropanolamine ligands with the beta(1)-AR was further characterized using beta-AR antagonists. Activation of beta(1)-AR by CGP 12177 or LY 362884 was observed to be significantly more resistant to blockade by beta-AR antagonists compared with activation by catecholamines. These results suggest that catecholamines and aryloxypropanolamines interact with distinct active conformations of the beta(1)-AR: a state that is responsive to catecholamines and is blocked with high affinity by CGP 12177 and LY 362884, and a novel state that is activated by aryloxypropanolamines but is resistant to blockade by standard beta-AR antagonists. Moreover, dependence of antagonist affinity on agonist structure is unprecedented, and its implications on the use of beta-AR agonists such as CGP 12177 in receptor classification are discussed.

[1]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[2]  P. Molenaar,et al.  Putative β4‐adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: comparison with atrial receptors and relationship to (−)‐[3H]‐CGP 12177 binding , 1999, British Journal of Pharmacology.

[3]  R. Lefkowitz,et al.  Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.

[4]  Y. Salomon.  Adenylate cyclase assay. , 1979, Advances in cyclic nucleotide research.

[5]  T. Kenakin.  The Schild regression in the process of receptor classification. , 1982, Canadian journal of physiology and pharmacology.

[6]  N. Mohell,et al.  The beta-adrenergic radioligand [3H]CGP-12177, generally classified as an antagonist, is a thermogenic agonist in brown adipose tissue. , 1989, The Biochemical journal.

[7]  E. J. Ariëns.  Intrinsic Activity: Partial Agonists and Partial Antagonists , 1983, Journal of cardiovascular pharmacology.

[8]  J. Granneman,et al.  Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat. , 1991, The American journal of physiology.

[9]  J. Granneman,et al.  Molecular cloning and expression of the rat beta 3-adrenergic receptor. , 1991, Molecular pharmacology.

[10]  Liaoyuan A. Hu,et al.  Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Simons,et al.  CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. , 1983, The Journal of biological chemistry.

[12]  J. Giacobino,et al.  (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice. , 1998, Molecular pharmacology.

[13]  M. Staehelin,et al.  Rapid and reversible disappearance of beta‐adrenergic cell surface receptors. , 1982, The EMBO journal.

[14]  A. Strosberg,et al.  Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor. , 1993, Molecular pharmacology.

[15]  P. Molenaar,et al.  Modulation of human cardiac function through 4 β-adrenoceptor populations , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  J. Granneman,et al.  β1-Adrenergic Receptors Mediate β3-Adrenergic-Independent Effects of CGP 12177 in Brown Adipose Tissue , 2000 .

[17]  Peter Molenaar,et al.  PROPOSAL FOR THE INTERACTION OF NON‐CONVENTIONAL PARTIAL AGONISTS AND CATECHOLAMINES WITH THE ‘PUTATIVE (β‐ADRENOCEPTOR’ IN MAMMALIAN HEART , 1997, Clinical and experimental pharmacology & physiology.

[18]  J. Granneman,et al.  Perinatal changes in the coupling of beta 1- and beta 3 adrenergic receptors to brown fat adenylyl cyclase. , 1992, The Journal of pharmacology and experimental therapeutics.

[19]  J. Arch,et al.  Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[20]  J. Granneman,et al.  Characterization of the human beta 3-adrenergic receptor gene. , 1993, Molecular pharmacology.

[21]  J. Granneman,et al.  Agonist interactions with chimeric and mutant beta1- and beta3-adrenergic receptors: involvement of the seventh transmembrane region in conferring subtype specificity. , 1998, Molecular pharmacology.

[22]  B. Malinowska,et al.  Further evidence for differences between cardiac atypical β‐adrenoceptors and brown adipose tissue β3‐adrenoceptors in the pithed rat , 1997 .

[23]  J. Granneman,et al.  Influence of cell type upon the desensitization of the beta 3-adrenergic receptor. , 1994, The Journal of pharmacology and experimental therapeutics.

[24]  M. Zuscik,et al.  Identification of a Conserved Switch Residue Responsible for Selective Constitutive Activation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[25]  N. Kotecha,et al.  The contribution of classical (beta1/2-) and atypical beta-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel beta3-adrenoceptor agonists of differing selectivities. , 1998, The Journal of pharmacology and experimental therapeutics.

[26]  R Seifert,et al.  Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. , 1999, Molecular pharmacology.

[27]  T. Bonner,et al.  Definition of pharmacological receptors. , 1992, Pharmacological reviews.

[28]  G. Barsh,et al.  Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Kenakin,et al.  On the importance of the "antagonist assumption" to how receptors express themselves. , 1995, Biochemical pharmacology.

[30]  S. Green,et al.  Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding , 1996, The Journal of Biological Chemistry.

[31]  C. Whitty,et al.  CGP 12177A modulates brown fat adenylate cyclase activity by interacting with two distinct receptor sites. , 1991, The Journal of pharmacology and experimental therapeutics.

[32]  J. Montastruc,et al.  Lipolytic effects of conventional β3‐adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4‐adrenoceptor , 1997, British journal of pharmacology.

[33]  P. Fishman,et al.  Anomalous behavior of CGP 12177A on beta 1-adrenergic receptors. , 1996, Journal of receptor and signal transduction research.

[34]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.

[35]  S. Tuc̆ek,et al.  Is the R and R dichotomy real? , 1997, Trends in pharmacological sciences.

[36]  P. Molenaar,et al.  Validity of (−)‐[3H]‐CGP 12177A as a radioligand for the ‘putative β4‐adrenoceptor’ in rat atrium , 1998, British journal of pharmacology.

[37]  L. Miller,et al.  Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. , 1998, The Journal of pharmacology and experimental therapeutics.

[38]  Walter Born,et al.  An Amylin Receptor Is Revealed Following Co-Transfection of a Calcitonin Receptor with Receptor Activity Modifying Proteins-1 or -3. , 1999, Endocrinology.

[39]  J. Giacobino,et al.  Metabolic response to various β‐adrenoceptor agonists in β3‐adrenoceptor knockout mice: Evidence for a new β‐adrenergic receptor in brown adipose tissue , 1998 .